Althea Technologies

The firm's business model is centered on providing a comprehensive suite of outsourced services that support pharmaceutical companies from early-stage clinical development through to commercial-scale manufacturing. Revenue is generated by offering services on a contractual basis. Althea specializes in biologics manufacturing, analytical development, and stability testing. A core area of its operations is drug product manufacturing, specifically aseptic fill and finish services for vials and syringes. The company serves a client base that ranges from emerging biotech startups to large pharmaceutical corporations.

Althea's service portfolio is extensive, covering upstream and downstream process development, complex formulation, and product release testing. A key offering is its proprietary Crystalomics® technology, a formulation platform designed for large-molecule products that need to be delivered in high concentrations or as sustained-release formulations. Another significant technology is the Corynex® protein expression system. In 2009, the company expanded its capabilities by opening a 30,000-square-foot commercial-scale cGMP manufacturing facility. A major milestone occurred in April 2013, when Althea Technologies was acquired by Ajinomoto Co., Inc. for approximately $175 million, subsequently becoming Ajinomoto Althea, Inc. In 2018, Ajinomoto Althea merged with OmniChem to form Ajinomoto Bio-Pharma Services, creating a global CDMO with facilities in the US and Europe.